Global acute myeloid leukemia (AML) treatment market is expected to grow at a compound annual growth rate (CAGR) of 11.4% during the forecast period of 2024-2032. This rapid growth is driven by the increasing incidence of leukemia, particularly among children, as well as advancements in treatment options and growing investments in research and development (R&D).